HK1083065A1 - Method for in vivo regulation of cardiac muscle contractility - Google Patents
Method for in vivo regulation of cardiac muscle contractilityInfo
- Publication number
- HK1083065A1 HK1083065A1 HK06104900.5A HK06104900A HK1083065A1 HK 1083065 A1 HK1083065 A1 HK 1083065A1 HK 06104900 A HK06104900 A HK 06104900A HK 1083065 A1 HK1083065 A1 HK 1083065A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cardiac muscle
- muscle contractility
- heart failure
- vivo regulation
- congestive heart
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 210000004165 myocardium Anatomy 0.000 title abstract 3
- 238000001727 in vivo Methods 0.000 title abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 abstract 1
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
- C12Y306/03008—Ca2+-transporting ATPase (3.6.3.8)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/342,120 US7745416B2 (en) | 1995-04-11 | 2003-01-13 | Method for in vivo regulation of cardiac muscle contractility |
PCT/US2004/000719 WO2004062618A2 (en) | 2003-01-13 | 2004-01-12 | Method for in vivo regulation of cardiac muscle contractility |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1083065A1 true HK1083065A1 (en) | 2006-06-23 |
Family
ID=32711653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06104900.5A HK1083065A1 (en) | 2003-01-13 | 2006-04-25 | Method for in vivo regulation of cardiac muscle contractility |
Country Status (11)
Country | Link |
---|---|
US (1) | US7745416B2 (es) |
EP (1) | EP1590001B1 (es) |
JP (1) | JP2006518996A (es) |
AT (1) | ATE416792T1 (es) |
AU (2) | AU2004204815B2 (es) |
CA (1) | CA2513249A1 (es) |
DE (1) | DE602004018269D1 (es) |
ES (1) | ES2318264T3 (es) |
HK (1) | HK1083065A1 (es) |
IL (1) | IL169663A (es) |
WO (1) | WO2004062618A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050095227A1 (en) * | 1997-07-22 | 2005-05-05 | The General Hospital Corporation | Treating heart failure |
WO2005023292A1 (en) | 2003-09-03 | 2005-03-17 | The General Hospital Corporation | Methods of treating restenosis |
US20060148742A1 (en) * | 2004-02-26 | 2006-07-06 | Kaye David M | Polynucleotide delivery to cardiac tissue |
EP1791432A4 (en) * | 2004-09-09 | 2010-07-07 | Gen Hospital Corp | MODULATION OF PHOSPHATASE ACTIVITY IN CARDIAC CELLS |
CA2658628A1 (en) * | 2006-07-25 | 2008-01-31 | Celladon Corporation | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
CA2692052A1 (en) * | 2007-06-18 | 2008-12-24 | Celladon Corporation | Serca2 therapeutic compositions and methods of use |
EP3156414B1 (en) * | 2007-09-26 | 2019-12-04 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
CA2715765A1 (en) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
US20180099029A9 (en) * | 2010-04-15 | 2018-04-12 | Mount Sinai School Of Medicine | Serca2 therapeutic compositions and methods of use |
EP2931892B1 (en) | 2012-12-12 | 2018-09-12 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
ES2658401T3 (es) | 2012-12-12 | 2018-03-09 | The Broad Institute, Inc. | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas |
WO2014204729A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
DK3011032T3 (da) * | 2013-06-17 | 2020-01-20 | Broad Inst Inc | Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler |
RU2716420C2 (ru) * | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
CN106062197A (zh) | 2013-06-17 | 2016-10-26 | 布罗德研究所有限公司 | 用于序列操纵的串联指导系统、方法和组合物的递送、工程化和优化 |
AU2014281027A1 (en) | 2013-06-17 | 2016-01-28 | Massachusetts Institute Of Technology | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
EP3080271B1 (en) | 2013-12-12 | 2020-02-12 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
AU2014361784A1 (en) * | 2013-12-12 | 2016-06-23 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders |
BR112016013547A2 (pt) | 2013-12-12 | 2017-10-03 | Broad Inst Inc | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos |
JP7103750B2 (ja) | 2013-12-12 | 2022-07-20 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのCRISPR-Cas系及び組成物の送達、使用及び治療適用 |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
MX2017016289A (es) | 2015-06-18 | 2018-08-15 | Broad Inst Inc | Mutaciones de la enzima crispr que reducen los efectos fuera del blanco. |
WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
US5658785A (en) * | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5792453A (en) | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
EP0760682A4 (en) * | 1995-02-28 | 1998-09-09 | Univ California | ANGIOGENIC THERAPY BY GENE TRANSFER |
US6306830B1 (en) * | 1996-09-05 | 2001-10-23 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
US6605274B1 (en) * | 1995-04-11 | 2003-08-12 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
US5919449A (en) * | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
US5797870A (en) * | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5846528A (en) * | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US5962313A (en) * | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
AU5819599A (en) * | 1998-09-11 | 2000-04-03 | Regents Of The University Of California, The | Recombinant adenovirus for tissue specific expression in heart |
DE69935078T2 (de) * | 1998-11-02 | 2007-11-15 | The Regents Of The University Of California, La Jolla | Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen |
US7078387B1 (en) * | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
WO2000038518A1 (en) * | 1998-12-28 | 2000-07-06 | Arch Development Corporation | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
CA2422078C (en) * | 2000-09-11 | 2011-08-09 | The Regents Of The University Of California | High efficiency cardiac gene transfer |
US20020159978A1 (en) * | 2001-02-06 | 2002-10-31 | James Allen | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions |
WO2005023292A1 (en) * | 2003-09-03 | 2005-03-17 | The General Hospital Corporation | Methods of treating restenosis |
-
2003
- 2003-01-13 US US10/342,120 patent/US7745416B2/en not_active Expired - Fee Related
-
2004
- 2004-01-12 CA CA002513249A patent/CA2513249A1/en not_active Abandoned
- 2004-01-12 WO PCT/US2004/000719 patent/WO2004062618A2/en active Application Filing
- 2004-01-12 JP JP2006500911A patent/JP2006518996A/ja active Pending
- 2004-01-12 AT AT04701534T patent/ATE416792T1/de not_active IP Right Cessation
- 2004-01-12 EP EP04701534A patent/EP1590001B1/en not_active Revoked
- 2004-01-12 AU AU2004204815A patent/AU2004204815B2/en not_active Ceased
- 2004-01-12 DE DE602004018269T patent/DE602004018269D1/de not_active Expired - Lifetime
- 2004-01-12 ES ES04701534T patent/ES2318264T3/es not_active Expired - Lifetime
-
2005
- 2005-07-13 IL IL169663A patent/IL169663A/en not_active IP Right Cessation
-
2006
- 2006-04-25 HK HK06104900.5A patent/HK1083065A1/xx not_active IP Right Cessation
-
2010
- 2010-06-10 AU AU2010202432A patent/AU2010202432A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2513249A1 (en) | 2004-07-29 |
EP1590001A4 (en) | 2006-02-01 |
AU2010202432A1 (en) | 2010-07-01 |
WO2004062618A3 (en) | 2004-12-09 |
IL169663A (en) | 2011-04-28 |
US20030211080A1 (en) | 2003-11-13 |
JP2006518996A (ja) | 2006-08-24 |
ATE416792T1 (de) | 2008-12-15 |
AU2004204815B2 (en) | 2010-03-11 |
US7745416B2 (en) | 2010-06-29 |
ES2318264T3 (es) | 2009-05-01 |
DE602004018269D1 (de) | 2009-01-22 |
EP1590001A2 (en) | 2005-11-02 |
WO2004062618A2 (en) | 2004-07-29 |
EP1590001B1 (en) | 2008-12-10 |
AU2004204815A1 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1083065A1 (en) | Method for in vivo regulation of cardiac muscle contractility | |
EP1773867A4 (en) | PROTEIN COMPOUNDS AND USES THEREOF | |
EP2851422A3 (en) | CD34neg stem cells for the treatment of gastrointestinal disorders | |
IL238490A0 (en) | Preparations and methods for regulating NK cell activity | |
ATE374251T1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
WO2005062881A3 (en) | Gene therapy using transposon-based vectors | |
WO2004065564A3 (en) | Electromagnetic activation of gene expression and cell growth | |
AU2002361327A1 (en) | Exogenous protein expression system in an avian system | |
PL2169063T3 (pl) | Kwas nukleinowy promotora pochodzący od bakterii z rodzaju Corynebacterium, kaseta ekspresyjna obejmująca promotor i wektor obejmujący kasetę, komórka gospodarza obejmująca wektor i sposób wyrażania genu z użyciem komórki | |
WO2006111387A3 (en) | Mammalian expression vector comprising the mcmv promoter and first intron of hcmv major immediate early gene | |
CA2217967A1 (en) | Augmentation in serca2 mediated calcium ion transport for regulation of cardiac muscle contractility | |
WO2021087296A8 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
ATE326523T1 (de) | Verfahren zur fermentativen herstellung von l- methionin | |
MX339227B (es) | Alimentacion alcalina. | |
WO2004033653A3 (en) | Gene regulation with aptamer and modulator complexes for gene therapy | |
WO1998010085A3 (en) | Gene therapy for congestive heart failure | |
WO2004076626A3 (en) | Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor | |
WO2008058752A3 (en) | Lentiviral vectors for gene transfer in quiescent (g0) cells | |
WO2002064746A3 (en) | Combined transductional and transcriptional targeting system for improved gene delivery | |
WO2003087330A3 (en) | Vac-bac shuttle vector system | |
WO2004003152A3 (en) | Sos1 inhibitors | |
AU7032600A (en) | Gene treatment to enhance feed efficiency and growth rate of livestock | |
WO2001055410A3 (en) | Ceramidase compositions and methods based thereon | |
WO2003088916A3 (en) | Compositions and methods for the acceleration of protein secretion dynamics | |
WO2001048164A3 (en) | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160112 |